On June 26, 2023 Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, reported that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 5,000 shares of common stock and (ii) restricted stock grants (the "Inducement Stock Grants") totaling 1,000 shares of common stock as a material inducement to the employment to one individual hired by Imunon during the second quarter of 2023 (Press release, IMUNON, JUN 26, 2023, View Source [SID1234632894]). The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Inducement Option Grants have an exercise price per share equal to $1.28, which is equal to the closing price of Imunon’s common stock as reported by Nasdaq on June 26, 2023. The Inducement Option Grants vest in quarters over four years with the vesting starting on the one-year anniversary of each employee’s first day of employment with the Company and thereafter vest in three additional installments so all Inducement Option Grants will be fully vested and exercisable as of June 26, 2027, subject to each employee’s continued service relationship with the Company on each such date. Each Inducement Option Grant has a ten-year term.
Each of the Inducement Stock Grants will vest on the one-year anniversary of each employee’s first date of employment with the Company and are subject to each such employee’s continued service relationship with the Company on such vesting date.